ArticleJournal of breast cancer2022
The Prediction of HER2-Targeted Treatment Response Using
Article in Journal of breast cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 7 citations in OpenAlex.
- Impact of HER2-targeted PET/CT imaging in patients with breast cancer and therapeutic response monitoring.The oncologist · 2025Trial
- Radiolabeled HER2-targeted molecular probes in breast cancer imaging: current knowledge and future prospective.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Molecular probes targeting HER2 PET/CT and their application in advanced breast cancer.Journal of cancer research and clinical oncology · 2024Review
- PET/MRI and Novel Targets for Breast Cancer.Biomedicines · 2024Review
- PET/CT and SPECT/CT Imaging of HER2-Positive Breast Cancer.Journal of clinical medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
Abstract
A 45-year-old woman diagnosed with breast cancer reported disease progression in the form of metastatic lung and recurrent breast lesions following chemotherapy and human epidermal growth factor receptor 2 (HER2)-targeted therapy. The patient underwent
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.